Highlights
- Tavapadon, a first-in-class selective D1/D5 partial agonist, met its primary endpoint in the Phase 3 TEMPO-3 trial, significantly increasing ‘good-on-time’ in Parkinson’s disease (PD) patients.
- The trial demonstrated a statistically significant increase of 1.10 hours in daily good-on-time compared to placebo (P < .001) over 26 weeks.
- Key secondary outcomes showed a reduction in daily ‘off-time’ by 0.94 hours more than placebo, addressing a critical unmet need in patients with levodopa-induced motor fluctuations.
- Tavapadon exhibited a favorable safety profile, with most adverse events categorized as mild to moderate, potentially avoiding some of the neuropsychiatric complications associated with traditional D2/D3-preferential agonists.
Background
Parkinson disease (PD) management is fundamentally predicated on dopaminergic replacement, primarily through oral levodopa. While levodopa remains the gold standard, its long-term use is frequently complicated by the development of motor fluctuations (the ‘wearing-off’ phenomenon) and dyskinesia. This ‘on-off’ cycle significantly degrades quality of life and increases the clinical burden on both patients and caregivers.
Traditionally, adjunctive therapies to levodopa include catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase type B (MAO-B) inhibitors, and dopamine agonists. However, currently available dopamine agonists (such as pramipexole or ropinirole) preferentially target D2 and D3 receptor subtypes. While effective in motor control, D2/D3 activation is associated with a specific profile of adverse events (AEs), including somnolence, peripheral edema, and impulse control disorders (ICDs). There is a significant clinical need for a therapy that provides the motor benefits of dopamine agonism while minimizing these dose-limiting toxicities. Tavapadon, a novel, oral, once-daily, selective D1/D5 receptor partial agonist, was developed to meet this challenge by targeting the direct pathway of the basal ganglia more specifically.
Key Content
The Mechanistic Approach: D1/D5 Selectivity
Unlike traditional agonists, tavapadon targets the D1 and D5 receptor families. Mechanistically, the D1-like receptors are primarily located on the ‘direct pathway’ of the basal ganglia, which facilitates movement. In contrast, D2-like receptors are concentrated on the ‘indirect pathway.’ Selective D1/D5 partial agonism is hypothesized to offer a more predictable motor response and a wider therapeutic window. By acting as a partial agonist, tavapadon may also modulate receptor signaling to avoid the overstimulation that leads to troublesome dyskinesia.
TEMPO-3: Trial Design and Participant Demographics
TEMPO-3 was a phase 3, double-blind, placebo-controlled randomized clinical trial conducted across 148 sites in 14 countries. The study period spanned from September 2020 to February 2024.
Eligible participants were adults with PD experiencing motor fluctuations despite receiving a stable dose of oral levodopa (≥400 mg daily). A total of 507 participants were randomized 1:1 to receive either flexible-dose tavapadon (5–15 mg once daily) or a matching placebo for 27 weeks. The mean age of the cohort was 64.9 years, with an average disease duration of 6.7 years and a baseline daily ‘off-time’ of approximately 5.5 hours.
Primary and Secondary Efficacy Outcomes
The primary efficacy endpoint was the change from baseline to week 26 in total daily ‘good-on-time,’ defined as time during which the patient has good mobility without troublesome dyskinesia.
Results revealed:
- Good-On-Time: Tavapadon increased daily good-on-time by 1.70 hours compared to 0.60 hours in the placebo group, representing a statistically significant treatment difference of 1.10 hours (95% CI, 0.60-1.70; P < .001).
- Off-Time: The key secondary endpoint, change in total daily ‘off-time,’ also favored tavapadon. Patients in the tavapadon arm experienced a reduction of 1.88 hours in off-time compared to 0.93 hours in the placebo arm, a net difference of -0.94 hours (95% CI, -1.48 to -0.41; P < .001).
Safety and Tolerability Profile
Safety is a paramount concern in PD therapy, especially regarding the potential for dyskinesia and psychiatric side effects. In TEMPO-3, 71.7% of the tavapadon group reported at least one AE compared to 55.1% in the placebo group. Crucially, 93.2% of these events were nonserious. The most common AEs observed with tavapadon included:
- Nausea (14.3%)
- Dyskinesia (10.0%)
- Dizziness (7.6%)
- Headache and Somnolence (reported in lower frequencies)
Notably, the incidence of troublesome dyskinesia remained low, supporting the ‘partial agonist’ hypothesis that tavapadon provides smoother motor control without the ‘peaks’ that typically trigger involuntary movements.
Expert Commentary
The TEMPO-3 trial results represent a significant milestone in the pharmacological management of Parkinson disease. For decades, the field has relied on D2-preferential agonists. The success of a D1/D5 selective agent validates a long-standing neurobiological hypothesis that targeting the direct pathway can yield clinically meaningful motor improvements.
One of the most compelling aspects of the tavapadon data is the quality of the ‘on-time.’ In clinical practice, clinicians often struggle with ‘on-time’ that is marred by dyskinesia; however, tavapadon specifically increased ‘good-on-time.’ Furthermore, the once-daily dosing regimen of tavapadon offers a clear advantage in treatment adherence compared to adjunctive therapies that require multiple daily doses.
However, some questions remain. While the safety profile appears favorable, longer-term data (beyond 26 weeks) will be essential to monitor for rare but serious side effects like valvulopathy or impulse control disorders, although the D1-selectivity may theoretically lower the risk for the latter compared to D3-preferential agents. Additionally, future studies should investigate the efficacy of tavapadon as a monotherapy in early-stage PD (the TEMPO-1 and TEMPO-2 trials) to determine if it can delay the necessity for levodopa initiation.
Conclusion
The TEMPO-3 trial provides robust evidence that tavapadon is an effective and well-tolerated adjunctive treatment for patients with Parkinson disease experiencing motor fluctuations. By increasing daily good-on-time by over an hour and significantly reducing off-time, tavapadon addresses the primary challenges of levodopa therapy. Its novel mechanism as a selective D1/D5 agonist offers a promising alternative to current D2-based treatments, potentially simplifying regimens with its once-daily oral administration. As the PD population continues to grow globally, tavapadon may soon become a vital component of the movement disorder specialist’s armamentarium.
References
- Fernandez HH, Isaacson SH, Hauser RA, et al. Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial. JAMA Neurol. 2026; PMID: 41860544.
- Katzenschlager R, et al. Fourteen-year follow-up of the UK PDSG Trial. Lancet Neurol. 2008;7(6):524-532.
- Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665-677.
